PDF herunterladen
Semin Neurol 2014; 34(04): 395-404
DOI: 10.1055/s-0034-1390388
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

IgG4-Related Disease and Other Causes of Inflammatory Meningeal Disease

Robert Carruthers
1   Department of Neurology, Brigham and Women's Hospital, Brookline, Massachusetts
,
Mollie Carruthers
2   Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
,
Emanuel Della-Torre
3   Department of Medicine and Clinical Immunology, IRCCS-San Raffaele Scientific Institute, Milan, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
04. November 2014 (online)

    Lizenzen und Reprints

Abstract

Immunoglobulin-4 (IgG4-) related disease is a newly described treatable condition that has recently expanded the differential diagnosis of inflammatory meningeal disorders. This review will discuss the main clinical and pathophysiological features of IgG4-related meningeal disease in the context of meningeal inflammatory disorders in general. Particular attention will be dedicated to the differential diagnosis and the different therapeutic approaches.

Keywords

pachymeningitis - IgG4-related disease - inflammatory meningeal disease
 

  • References

  • 1 Wallace ZS, Carruthers MN, Khosroshahi A , et al. IgG4-related disease and hypertrophic pachymeningitis. Medicine (Baltimore) 2013; 92 (4) 206-216
    CrossrefPubMedGoogle Scholar
  • 2 Lindstrom KM, Cousar JB, Lopes MB. IgG4-related meningeal disease: clinico-pathological features and proposal for diagnostic criteria. Acta Neuropathol 2010; 120 (6) 765-776
    CrossrefPubMedGoogle Scholar
  • 3 Shapiro KA, Bové RM, Volpicelli ER, Mallery RM, Stone JH. Relapsing course of immunoglobulin G4-related pachymeningitis. Neurology 2012; 79 (6) 604-606
    CrossrefPubMedGoogle Scholar
  • 4 Kim EH, Kim SH, Cho JM, Ahn JY, Chang JH. Immunoglobulin G4-related hypertrophic pachymeningitis involving cerebral parenchyma. J Neurosurg 2011; 115 (6) 1242-1247
    CrossrefPubMedGoogle Scholar
  • 5 Kosakai A, Ito D, Yamada S, Ideta S, Ota Y, Suzuki N. A case of definite IgG4-related pachymeningitis. Neurology 2010; 75 (15) 1390-1392
    CrossrefPubMedGoogle Scholar
  • 6 Regev K, Nussbaum T, Cagnano E, Giladi N, Karni A. Central nervous system manifestation of IgG4-related disease. JAMA Neurol 2014; 71 (6) 767-770
    CrossrefPubMedGoogle Scholar
  • 7 Shimatsu A, Oki Y, Fujisawa I, Sano T. Pituitary and stalk lesions (infundibulo-hypophysitis) associated with immunoglobulin G4-related systemic disease: an emerging clinical entity. Endocr J 2009; 56 (9) 1033-1041
    CrossrefPubMedGoogle Scholar
  • 8 Choi SH, Lee SH, Khang SK, Jeon SR. IgG4-related sclerosing pachymeningitis causing spinal cord compression. Neurology 2010; 75 (15) 1388-1390
    CrossrefPubMedGoogle Scholar
  • 9 Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366 (6) 539-551
    CrossrefPubMedGoogle Scholar
  • 10 Comings DE, Skubi KB, Van Eyes J, Motulsky AG. Familial multifocal fibrosclerosis. Findings suggesting that retroperitoneal fibrosis, mediastinal fibrosis, sclerosing cholangitis, Riedel's thyroiditis, and pseudotumor of the orbit may be different manifestations of a single disease. Ann Intern Med 1967; 66 (5) 884-892
    CrossrefPubMedGoogle Scholar
  • 11 Neild GH, Rodriguez-Justo M, Wall C, Connolly JO. Hyper-IgG4 disease: report and characterisation of a new disease. BMC Med 2006; 4: 23
    CrossrefPubMedGoogle Scholar
  • 12 Hamano H, Kawa S, Horiuchi A , et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001; 344 (10) 732-738
    Google Scholar
  • 13 Kamisawa T, Funata N, Hayashi Y , et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003; 38 (10) 982-984
    CrossrefPubMedGoogle Scholar
  • 14 Carruthers MN, Khosroshahi A, Augustin T, Deshpande V, Stone JH. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis 2014;
    PubMedGoogle Scholar
  • 15 Khosroshahi A, Cheryk LA, Carruthers MN, Edwards JA, Bloch DB, Stone JH. Brief report: spuriously low serum IgG4 concentrations caused by the prozone phenomenon in patients with IgG4-related disease. Arthritis Rheum (Munch) 2014; 66 (1) 213-217
    CrossrefPubMedGoogle Scholar
  • 16 Zen Y, Nakanuma Y. IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol 2010; 34 (12) 1812-1819
    CrossrefPubMedGoogle Scholar
  • 17 Hart PA, Topazian MD, Witzig TE , et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 2013; 62 (11) 1607-1615
    CrossrefPubMedGoogle Scholar
  • 18 Deshpande V, Zen Y, Chan JK , et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012; 25 (9) 1181-1192
    CrossrefPubMedGoogle Scholar
  • 19 Della Torre E, Bozzolo EP, Passerini G, Doglioni C, Sabbadini MG. IgG4-related pachymeningitis: evidence of intrathecal IgG4 on cerebrospinal fluid analysis. Ann Intern Med 2012; 156 (5) 401-403
    PubMedGoogle Scholar
  • 20 Della-Torre E, Passerini G, Furlan R , et al. Cerebrospinal fluid analysis in immunoglobulin G4-related hypertrophic pachymeningitis. J Rheumatol 2013; 40 (11) 1927-1929
    CrossrefPubMedGoogle Scholar
  • 21 Nirula A, Glaser SM, Kalled SL, Taylor FR. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol 2011; 23 (1) 119-124
    CrossrefPubMedGoogle Scholar
  • 22 Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009; 39 (4) 469-477
    CrossrefPubMedGoogle Scholar
  • 23 Mattoo H, Della-Torre E, Mahajan VS, Stone JH, Pillai S. Circulating Th2 memory cells in IgG4-related disease are restricted to a defined subset of subjects with atopy. Allergy 2014; 69 (3) 399-402
    CrossrefPubMedGoogle Scholar
  • 24 Della Torre E, Mattoo H, Mahajan VS, Carruthers M, Pillai S, Stone JH. Prevalence of atopy, eosinophilia, and IgE elevation in IgG4-related disease. Allergy 2014; 69 (2) 269-272
    CrossrefPubMedGoogle Scholar
  • 25 Jeannin P, Lecoanet S, Delneste Y, Gauchat JF, Bonnefoy JY. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol 1998; 160 (7) 3555-3561
    PubMedGoogle Scholar
  • 26 Satoguina JS, Weyand E, Larbi J, Hoerauf A. T regulatory-1 cells induce IgG4 production by B cells: role of IL-10. J Immunol 2005; 174 (8) 4718-4726
    CrossrefPubMedGoogle Scholar
  • 27 Della-Torre E, Galli L, Franciotta D , et al. Diagnostic value of IgG4 Indices in IgG4-related hypertrophic pachymeningitis. J Neuroimmunol 2014; 266 (1-2) 82-86
    CrossrefPubMedGoogle Scholar
  • 28 Reiber H, Peter JB. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci 2001; 184 (2) 101-122
    CrossrefPubMedGoogle Scholar
  • 29 Tomiyama T, Uchida K, Matsushita M , et al. Comparison of steroid pulse therapy and conventional oral steroid therapy as initial treatment for autoimmune pancreatitis. J Gastroenterol 2011; 46 (5) 696-704
    CrossrefPubMedGoogle Scholar
  • 30 Ghazale A, Chari ST, Zhang L , et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134 (3) 706-715
    CrossrefPubMedGoogle Scholar
  • 31 Sandanayake NS, Church NI, Chapman MH , et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2009; 7 (10) 1089-1096
    CrossrefPubMedGoogle Scholar
  • 32 Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010; 62 (6) 1755-1762
    CrossrefPubMedGoogle Scholar
  • 33 Khosroshahi A, Carruthers MN, Deshpande V, Unizony S, Bloch DB, Stone JH. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore) 2012; 91 (1) 57-66
    CrossrefPubMedGoogle Scholar
  • 34 Stone JH. Rituximab in IgG4-related Disease: A Phase 1-2 Trial. 2012. Available at: http://clinicaltrials.gov/show/NCT01584388 . Accessed October 1, 2014
    PubMedGoogle Scholar
  • 35 Woywodt A, Matteson EL. Wegener's granulomatosis—probing the untold past of the man behind the eponym. Rheumatology (Oxford) 2006; 45 (10) 1303-1306
    CrossrefPubMedGoogle Scholar
  • 36 Di Comite G, Bozzolo EP, Praderio L, Tresoldi M, Sabbadini MG. Meningeal involvement in Wegener's granulomatosis is associated with localized disease. Clin Exp Rheumatol 2006; 24 (2) (Suppl. 41) S60-S64
    PubMedGoogle Scholar
  • 37 Yokoseki A, Saji E, Arakawa M , et al. Hypertrophic pachymeningitis: significance of myeloperoxidase anti-neutrophil cytoplasmic antibody. Brain 2014; 137 (Pt 2) 520-536
    CrossrefPubMedGoogle Scholar
  • 38 Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and its neurological manifestations. Arch Neurol 1985; 42 (9) 909-917
    CrossrefPubMedGoogle Scholar
  • 39 Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM 2009; 102 (7) 449-460
    CrossrefPubMedGoogle Scholar
  • 40 Langrand C, Bihan H, Raverot G , et al. Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients. QJM 2012; 105 (10) 981-995
    CrossrefPubMedGoogle Scholar
  • 41 Ranoux D, Devaux B, Lamy C, Mear JY, Roux FX, Mas JL. Meningeal sarcoidosis, pseudo-meningioma, and pachymeningitis of the convexity. J Neurol Neurosurg Psychiatry 1992; 55 (4) 300-303
    CrossrefPubMedGoogle Scholar
  • 42 Riancho-Zarrabeitia L, Delgado-Alvarado M, Riancho J , et al. Anti-TNF-α therapy in the management of severe neurosarcoidosis: a report of five cases from a single centre and literature review. Clin Exp Rheumatol 2014; 32 (2) 275-284
    PubMedGoogle Scholar
  • 43 Starosta MA, Brandwein SR. Clinical manifestations and treatment of rheumatoid pachymeningitis. Neurology 2007; 68 (13) 1079-1080
    CrossrefPubMedGoogle Scholar
  • 44 Jones SE, Belsley NA, McLoud TC, Mullins ME. Rheumatoid meningitis: radiologic and pathologic correlation. AJR Am J Roentgenol 2006; 186 (4) 1181-1183
    CrossrefPubMedGoogle Scholar
  • 45 Bathon JM, Moreland LW, DiBartolomeo AG. Inflammatory central nervous system involvement in rheumatoid arthritis. Semin Arthritis Rheum 1989; 18 (4) 258-266
    CrossrefPubMedGoogle Scholar
  • 46 Ii Y, Kuzuhara S. Rheumatoid cranial pachymeningitis successfully treated with long-term corticosteroid. Rheumatol Int 2009; 29 (5) 583-585
    CrossrefPubMedGoogle Scholar
  • 47 Kato T, Hoshi K, Sekijima Y , et al. Rheumatoid meningitis: an autopsy report and review of the literature. Clin Rheumatol 2003; 22 (6) 475-480
    CrossrefPubMedGoogle Scholar
  • 48 Markenson JA, McDougal JS, Tsairis P, Lockshin MD, Christian CL. Rheumatoid meningitis: a localized immune process. Ann Intern Med 1979; 90 (5) 786-789
    CrossrefPubMedGoogle Scholar
  • 49 Xia Z, Chen-Plotkin A, Schmahmann JD. Hypertrophic pachymeningitis and cerebral venous sinus thrombosis in inflammatory bowel disease. J Clin Neurosci 2010; 17 (11) 1454-1456
    CrossrefPubMedGoogle Scholar
  • 50 International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335 (8697) 1078-1080
    PubMedGoogle Scholar
  • 51 Kalra S, Silman A, Akman-Demir G , et al. Diagnosis and management of neuro-Behçet's disease: international consensus recommendations. J Neurol 2013;
    PubMedGoogle Scholar
  • 52 Akman-Demir G, Serdaroglu P, Tasçi B. The Neuro-Behçet Study Group. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. Brain 1999; 122 (Pt 11) 2171-2182
    CrossrefPubMedGoogle Scholar
  • 53 Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications in Behçet's syndrome. Brain 1999; 122 (Pt 11) 2183-2194
    CrossrefPubMedGoogle Scholar
  • 54 Pipitone N, Olivieri I, Padula A , et al. Infliximab for the treatment of neuro-Behçet's disease: a case series and review of the literature. Arthritis Rheum 2008; 59 (2) 285-290
    CrossrefPubMedGoogle Scholar
  • 55 Goldgeier MH, Klein LE, Klein-Angerer S, Moellmann G, Nordlund JJ. The distribution of melanocytes in the leptomeninges of the human brain. J Invest Dermatol 1984; 82 (3) 235-238
    CrossrefPubMedGoogle Scholar
  • 56 Kamondi A, Szegedi A, Papp A, Seres A, Szirmai I. Vogt-Koyanagi-Harada disease presenting initially as aseptic meningoencephalitis. Eur J Neurol 2000; 7 (6) 719-722
    CrossrefPubMedGoogle Scholar
  • 57 Nakamura S, Nakazawa M, Yoshioka M , et al. Melanin-laden macrophages in cerebrospinal fluid in Vogt-Koyanagi-Harada syndrome. Arch Ophthalmol 1996; 114 (10) 1184-1188
    CrossrefPubMedGoogle Scholar
  • 58 Greco A, Fusconi M, Gallo A , et al. Vogt-Koyanagi-Harada syndrome. Autoimmun Rev 2013; 12 (11) 1033-1038
    CrossrefPubMedGoogle Scholar
  • 59 Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS, Kangave D, Al-Muammar AM. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol (Copenh) 2012; 90 (8) e603-e608
    CrossrefPubMedGoogle Scholar
  • 60 Liebow AA, Carrington CR, Friedman PJ. Lymphomatoid granulomatosis. Hum Pathol 1972; 3 (4) 457-558
    CrossrefPubMedGoogle Scholar
  • 61 Jaffe ES, Wilson WH. Lymphomatoid granulomatosis: pathogenesis, pathology and clinical implications. Cancer Surv 1997; 30: 233-248
    PubMedGoogle Scholar
  • 62 Patsalides AD, Atac G, Hedge U , et al. Lymphomatoid granulomatosis: abnormalities of the brain at MR imaging. Radiology 2005; 237 (1) 265-273
    CrossrefPubMedGoogle Scholar
  • 63 Wilson WH, Grossbard ML, Pittaluga S , et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002; 99 (8) 2685-2693
    CrossrefPubMedGoogle Scholar
  • 64 Chan SK, Cheuk W, Chan KT, Chan JK. IgG4-related sclerosing pachymeningitis: a previously unrecognized form of central nervous system involvement in IgG4-related sclerosing disease. Am J Surg Pathol 2009; 33 (8) 1249-1252
    CrossrefPubMedGoogle Scholar
  • 65 Kato K, Tamano Y, Namioka A , et al. [Hypertrophic pachymeningitis associated with autoimmune pancreatitis examined for IgG4 related disease: a case report]. No Shinkei Geka 2011; 39 (8) 763-768
    PubMedGoogle Scholar
  • 66 Moss HE, Mejico LJ, de la Roza G, Coyne TM, Galetta SL, Liu GT. IgG4-related inflammatory pseudotumor of the central nervous system responsive to mycophenolate mofetil. J Neurol Sci 2012; 318 (1-2) 31-35
    CrossrefPubMedGoogle Scholar
  • 67 Norikane T, Yamamoto Y, Okada M , et al. Hypertrophic cranial pachymeningitis with IgG4-positive plasma cells detected by C-11 methionine PET. Clin Nucl Med 2012; 37 (1) 108-109
    CrossrefPubMedGoogle Scholar
  • 68 Tajima Y, Mito Y. Cranial neuropathy because of IgG4-related pachymeningitis; intracranial and spinal mass lesions. BMJ Case Rep 2012; doi:10.1136/bcr-2012-006471
    PubMedGoogle Scholar
  • 69 Yamashita H, Takahashi Y, Ishiura H, Kano T, Kaneko H, Mimori A. Hypertrophic pachymeningitis and tracheobronchial stenosis in IgG4-related disease: case presentation and literature review. Intern Med 2012; 51 (8) 935-941
    CrossrefPubMedGoogle Scholar
  • 70 Lin CK, Lai DM. IgG4-related intracranial hypertrophic pachymeningitis with skull hyperostosis: a case report. BMC Surg 2013; 13: 37
    CrossrefPubMedGoogle Scholar
  • 71 Imbergamo S, Campagnolo M, Manara R, Marino F, Adami F, Briani C. Teaching NeuroImages: multifocal neurologic involvement as the only manifestation of IgG4-related disease. Neurology 2013; 80 (4) e40-e41
    CrossrefPubMedGoogle Scholar
  • 72 Utsuki S, Kijima C, Fujii K, Miyakawa S, Iizuka T, Hara A. Investigation of IgG4-positive cell infiltration in biopsy specimens from cases of hypertrophic pachymeningitis. Clin Neuropathol 2013; 32 (2) 84-90
    CrossrefPubMedGoogle Scholar
  • 73 Lipton S, Warren G, Pollock J, Schwab P. IgG4-related disease manifesting as pachymeningitis and aortitis. J Rheumatol 2013; 40 (7) 1236-1238
    CrossrefPubMedGoogle Scholar
  • 74 Makino S, Tanaka Y. A case of hypertrophic pachymeningitis with elevated serum IgG4. J Clin Exp Opthalmol 2013; 4: 260
    PubMedGoogle Scholar
  • 75 Tanboon J, Felicella MM, Bilbao J, Mainprize T, Perry A. Probable IgG4-related pachymeningitis: a case with transverse sinus obliteration. Clin Neuropathol 2013; 32 (4) 291-297
    CrossrefPubMedGoogle Scholar
  • 76 Hyun JW, Kim SH, Yoo H, Hong EK, Huh SY, Kim HJ. Steroid-resistant relapsing IgG4-related pachymeningitis treated with methotrexate. JAMA Neurol 2014; 71 (2) 222-225
    CrossrefPubMedGoogle Scholar
  • 77 Mehta SH, Switzer JA, Biddinger P, Rojiani AM. IgG4-related leptomeningitis: a reversible cause of rapidly progressive cognitive decline. Neurology 2014; 82 (6) 540-542
    CrossrefPubMedGoogle Scholar